Shennon Biotechnologies, a biotechnology company focused on precision immunotherapies for solid tumors, has secured $12 million in new financing. The round included participation from Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures and Saras Capital, alongside existing investors DCVC, Foundation Capital and AV8 Ventures. This latest raise brings the company's total funding to $25 million since its founding in 2021.
Financing and Leadership Transition
The financing will support the continued development of ShennonBio's integrated technology platform and its emerging oncology pipeline. In conjunction with the funding, the company appointed Cyril Konto, M.D., as chief executive officer, signaling a transition toward development-stage execution. Founder Li Sun, Ph.D., will move from chief executive officer to president and chief technology officer, retaining responsibility for scientific strategy, technology development and pipeline innovation.
Integrated Discovery Engine
ShennonBio has built a proprietary technology engine that spans target discovery, ultra-high-throughput functional screening, computational binder prediction and optimization, and AI-enabled safety assessment. A central element is the TCELERATOR platform, which profiles more than 10 million single-cell interactions at once and identifies functional leads in a single experiment. This unified system is supported by proprietary human tumor datasets and an expanding network of academic and clinical collaborators.
Dual T-Cell Engager Strategy
The company is advancing both antibody-based T-cell engagers, which address targets on the surface of tumor cells, and TCR-based T-cell engagers, which can potentially reach intracellular cancer targets presented through HLA. This dual approach aims to substantially expand the universe of cancer biology that T-cell engagers can address. ShennonBio has assembled data from more than 10,000 tumor samples and 11 million single cells across more than 15 collaborating institutions.
Initial Oncology Pipeline
ShennonBio has translated its platform into three initial oncology programs spanning both antibody-based and TCR-based approaches. SBT-121 is a dual-targeting trispecific antibody-based T-cell engager for small cell lung cancer, while SBT-201 is an antibody-based T-cell engager for ovarian cancer. SBT-425 is a TCR-based T-cell engager being developed for hepatocellular carcinoma.
CEO Experience and Strategy
Dr. Konto brings more than 20 years of oncology drug development, company building and strategic transaction experience to ShennonBio. Most recently, as president and chief executive officer of Ichnos Glenmark Innovation, he led an operational transformation and built the company's multispecifics franchise. Under his leadership, Ichnos completed an AbbVie partnership for a Phase 1 trispecific T-cell engager with up to $1.9 billion in total potential value plus royalties.
Near-Term Clinical Goals
Over the next two years, ShennonBio plans to advance a development candidate toward an IND filing and Phase 1 clinical development. The company also intends to pursue licensing opportunities for selected therapeutic programs and explore partnerships around its platform capabilities. These capabilities include binder prediction and generation, clinical toxicity prediction and the use of its proprietary datasets.
The $12 million financing and expanded leadership team mark an important transition for ShennonBio as it moves from platform building to clinical development. With a dual T-cell engager strategy, a growing proprietary dataset and three disclosed oncology programs, the company is positioning itself to address challenging solid tumors. Its focus over the coming years will be on advancing lead candidates toward the clinic and forming partnerships that can broaden the reach of its precision immunotherapy platform.